RA
TCRT icon

Royce & Associates’s Alaunos Therapeutics TCRT Stock Holding History

Royce & Associates’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,787
Closed -$708K – 1379
2014
Q3 		$708K Hold
1,787
– – ﹤0.01% 1173
2014
Q2 		$1.08M Sell
1,787
-420
-19% -$234K ﹤0.01% 1136
2014
Q1 		$1.52M Sell
2,207
-233
-10% -$156K ﹤0.01% 1096
2013
Q4 		$1.59M Sell
2,440
-1,400
-36% -$834K ﹤0.01% 1107
2013
Q3 		$2.27M Sell
3,840
-560
-13% -$252K 0.01% 1042
2013
Q2 		$1.39M Buy
+4,400
New +$1.22M ﹤0.01% 1110

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
MP
MSD Partners New York $76.8M AUM 34.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Royce & Associates's TCRT Position: Q4 2014 in Review

Royce & Associates sold out of Alaunos Therapeutics (TCRT) in Q4 2014, closing a stake of 1,787 shares — an estimated $708K sold.

Royce & Associates first reported a position in TCRT in Q2 2013 and held it in 6 quarters. The position peaked at $2.27M in Q3 2013. 85 funds tracked by Wall St. Rank hold TCRT as of Q4 2014.

  • Royce & Associates reported no remaining Alaunos Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Royce & Associates sold 1,787 Alaunos Therapeutics shares in Q4 2014, an estimated $708K.
  • Royce & Associates first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 6 quarters.
  • Royce & Associates's Alaunos Therapeutics position peaked at $2.27M in Q3 2013.
  • 85 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2014.

Based on Royce & Associates's 13F filing for Q4 2014, filed 9 Feb 2015.